Meeting
2023 ASCO Annual Meeting
The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.
Authors
Merve Kaya
Leiden University Medical Center, Leiden, Netherlands
Merve Kaya , Nanda Horeweg , Alexandra Leary , Stephen Welch , Stefan Kommoss , Nicola Weidner , Francesco Fanfani , Domenica Lorusso , John McGrane , Toon Van Gorp , Ingrid Boere , Anneke M. Westermann , Joan B. Heijns , Hein Putter , Karen Verhoeven-Adema , Vincent T.H.B.M. Smit , Carien L. Creutzberg , Tjalling Bosse , Judith R. Kroep
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT05255653
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5633)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5633
Abstract #
TPS5633
Poster Bd #
317b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
First Author: Florence Joly
Poster
2021 ASCO Annual Meeting
ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.
First Author: Toon Van Gorp
Poster
2020 ASCO Virtual Scientific Program
DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).
First Author: Shannon Neville Westin
First Author: B.J. Rimel